Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of post-durvalumab treatment cohorts in relapsed stage III NSCLC
2024-520081-65-00Phase 2Authorised
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Feb 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Fondazione Ricerca Traslazionale. Primary endpoints: Overall survival in Cohort A and Overall survival in Cohort B. Planned start Feb 2025; status: authorised.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-520081-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520081-65-00.